Signed in as:
filler@godaddy.com
RUO Semaglutide Cagrillintide
.jpeg/:/cr=t:11.11%25,l:0%25,w:100%25,h:88.89%25/rs=w:1209,h:605,cg:true)
Research on Bioavailability,, Oral Delivery Peptides
Cagrilintide is a long-acting amylin analog that works by mimicking the actions of the natural hormone amylin, which is co-secreted with insulin. It acts on amylin receptors and the calcitonin receptors to reduce food craving and increase satiety. Oral bioavailability is a key attribute of a peptide drug candidate and a significant challenge in peptide development. Zeptide Pharma specializes in developing products for further studies in the area of weight management
NAD+ Regenerative Medicine
NAD stands for nicotinamide adenine dinucleotide, a crucial coenzyme found in all living cells that plays a vital role in various metabolic processes. NAD is essential for energy production, DNA repair, and cell signaling. Its levels decline with age, and research suggests boosting NAD could be beneficial for health and potentially slow down aspects of aging. All Zeptide Pharma solid peptide delivery products contain NAD+ as the base, along with lipid-based drug delivery systems, to enhance peptide bioavailability and overall well-being. We create health!
CagriSema Formulation
Early Phase CagriSema oral peptide innovation formulation faced challenging properties, such as peptides with limited solubility, permeability, a very low
drug load, high potency, and limited stability. At Zeptide Pharma, we use an advanced oral solid-dose delivery system to develop peptide drugs that are bioequivalent to injectables for researchers. This approach is said to save pain at injection sites and minimize other bodily reactions to needles—our enabling technologies, including micronization, address solubility-induced absorption issues.
CagriSema Permeability Enhancers
For institutions researching peptides with limited bioavailability due to poor intestinal barrier permeability, lipid-based or permeation-enhancer-based formulation technologies are used. To address these challenges, we employ innovative formulation approaches to develop prototypes for oral peptide delivery employing SNAC molecular entities.
Proven Sterile Liquid CagriSema Manufacturing Expertise
Sterile Liquid Peptide Manufacturing
Sterile RUO CagriSema manufacturing requires dedicated, specialized capabilities that comply with FDA aseptic guidance and EMA regulatory requirements. With our extensive experience in the manufacturing of sterile solutions and liquids, we offer a wide variety of delivery systems, including vials, Pre-Filled Syringes (PFS), and ampules. Our state-of-the-art cGMP facility and equipment design, combined with highly skilled and trained personnel, are pivotal for the success of your sterile CagriSema manufacturing.
Effective Oral Drug Delivery-SNAC
SNAC is a synthetic N-acylated amino acid derivative of salicylic acid, used as an intestinal permeation enhancer. SNAC adheres to the gastric mucosa along with peptides to facilitate permeation and absorption. Oral semaglutide (Rybelsus®), the first oral peptide drug, was approved by the FDA and EMA in September 2019 and March 2020, respectively, bringing SNAC into the global public eye. Lozenges and sublingual drug delivery have proven to have similar bioavailability as injectable dosages for candidates who cannot swallow solid pills. Selecting the proper CGMP contract Manufacturer to produce your oral solid peptide dosage form is an important decision. USA Bachem Pharma is your partner of choice for Peptide Oral Solid Dose (OSD) formulation development and manufacturing. We create healthy options for you to choose.
Solid Suport through all Phases of Drug Development
We accompany you throughout the lifecycle of your products, from early-phase development and validation to commercial manufacturing and packaging. Additionally, we handle APIs down to the picogram-per-cubic-meter level.
Formulation Development, RUO & Commercial Manufacturing
Our Conventional processing technologies are:
- Blending
- Roller compaction
- High shear and fluid bed granulation, aqueous and organic solvents
- Tablet compression and coating (aesthetic and enteric)
- Encapsulation
Solutions for APIs with bioavailability challenges are:
- Spray drying
- Hot melt extrusion
- Micronization
- Nanomilling
- Lipid-based formulations
- Immediate and modified release formulations
- Powders, granules, pellets
- Coated and uncoated tablets, mini tablets
- Sublingual HPMC capsules
- Blister, bottle, and sachet packaging
Oral Peptides Base Formulation consists of:
- NAD+
- Niacinamide
- Vitamin B12
- Vitamin C
- SNAC
- Plus the desired Peptide
RUO Dulaglutide Liraglutide Exenatide
Our three Texas facilities and two California locations are dedicated to the development and production of peptide dosage forms for RUO and possess expertise in conventional processing technologies, including wet and dry granulation and fluid-bed techniques. We specialize in peptide lyophilized pellets comprising direct API and powders.